[go: up one dir, main page]

MX2020011552A - Combinaciones de variantes de anticuerpos y usos de las mismas. - Google Patents

Combinaciones de variantes de anticuerpos y usos de las mismas.

Info

Publication number
MX2020011552A
MX2020011552A MX2020011552A MX2020011552A MX2020011552A MX 2020011552 A MX2020011552 A MX 2020011552A MX 2020011552 A MX2020011552 A MX 2020011552A MX 2020011552 A MX2020011552 A MX 2020011552A MX 2020011552 A MX2020011552 A MX 2020011552A
Authority
MX
Mexico
Prior art keywords
combinations
antibodies
antibody variant
amino acid
acid substitutions
Prior art date
Application number
MX2020011552A
Other languages
English (en)
Inventor
Aran Frank Labrijn
Janine Schuurman
Jong Rob De
Kristin Strumane
Simone Oostindie
Frank Beurskens
Kreuk Bart-Jan De
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of MX2020011552A publication Critical patent/MX2020011552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan combinaciones de primero y segundo anticuerpos que tienen funciones efectoras de Fc modificadas que resultan de sustituciones de aminoácidos en la región Fc, las sustituciones de aminoácidos permiten la activación codependiente de funciones efectoras tales como CDC y/o ADCC. También se proporcionan combinaciones de primero y segundo anticuerpos que tienen actividad agonista o actividad agonista potenciada como resultado de sustituciones de aminoácidos en la región Fc en donde la actividad agonista es codependiente tanto de un primero como de un segundo anticuerpos.
MX2020011552A 2018-05-03 2019-05-03 Combinaciones de variantes de anticuerpos y usos de las mismas. MX2020011552A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201800195 2018-05-03
DKPA201800644 2018-09-26
PCT/EP2019/061455 WO2019211472A1 (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Publications (1)

Publication Number Publication Date
MX2020011552A true MX2020011552A (es) 2020-11-24

Family

ID=66476613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011552A MX2020011552A (es) 2018-05-03 2019-05-03 Combinaciones de variantes de anticuerpos y usos de las mismas.

Country Status (13)

Country Link
US (1) US12338289B2 (es)
EP (1) EP3788074A1 (es)
JP (2) JP7649139B2 (es)
KR (1) KR20210008380A (es)
CN (1) CN112839958A (es)
AU (1) AU2019264217A1 (es)
BR (1) BR112020022179A2 (es)
CA (1) CA3098486A1 (es)
MA (1) MA52485A (es)
MX (1) MX2020011552A (es)
PH (1) PH12020551808A1 (es)
SG (1) SG11202010601VA (es)
WO (1) WO2019211472A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945021B (zh) 2017-02-10 2025-09-12 根马布私人有限公司 多肽变体及其用途
CN115702164A (zh) * 2020-04-17 2023-02-14 詹森生物科技公司 生物合成糖蛋白群体
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN116964085A (zh) * 2021-03-12 2023-10-27 根马布股份公司 非激活抗体变体
US20250230254A1 (en) * 2021-10-20 2025-07-17 Janssen Biotech, Inc. Biosynthetic bioparatopic or bispecific binding molecules with enhanced effector functions
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
WO2008157379A2 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
KR20110104032A (ko) 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
DK2430051T3 (en) 2009-05-14 2016-07-04 Inst Nat De La Santé Et De La Rech Medicale Compositions containing antibodies for the treatment of CD5 + HLA-DR + B- or T-cell-related diseases
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
CN106046159B (zh) 2010-03-12 2020-06-16 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2802782C (en) 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
KR101612999B1 (ko) 2010-08-24 2016-04-15 로슈 글리카트 아게 활성화가능 이중특이적 항체
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
CN114163530B (zh) 2012-04-20 2025-04-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
ES2758979T3 (es) 2012-07-06 2020-05-07 Genmab Bv Proteína dimérica con mutaciones triples
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
EA201500741A1 (ru) 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
EP3131926A1 (en) 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
EP3280736A1 (en) * 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
SG11201803956UA (en) 2015-12-01 2018-06-28 Genmab Bv Anti-dr5 antibodies and methods of use thereof
EP3397646A1 (en) * 2015-12-28 2018-11-07 Massachusetts Institute of Technology Bispecific antibodies having constant region mutations and uses therefor
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
CN110945021B (zh) 2017-02-10 2025-09-12 根马布私人有限公司 多肽变体及其用途
US20200270359A1 (en) 2017-03-31 2020-08-27 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP2020522543A (ja) 2017-06-07 2020-07-30 ゲンマブ ビー．ブイ． 変異ＩｇＧ六量体に基づく治療用抗体
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof

Also Published As

Publication number Publication date
EP3788074A1 (en) 2021-03-10
US12338289B2 (en) 2025-06-24
AU2019264217A1 (en) 2020-12-17
US20210238296A1 (en) 2021-08-05
PH12020551808A1 (en) 2021-07-26
JP2025085008A (ja) 2025-06-03
CN112839958A (zh) 2021-05-25
JP7649139B2 (ja) 2025-03-19
MA52485A (fr) 2021-03-10
KR20210008380A (ko) 2021-01-21
SG11202010601VA (en) 2020-11-27
CA3098486A1 (en) 2019-11-07
BR112020022179A2 (pt) 2021-02-02
JP2021522303A (ja) 2021-08-30
WO2019211472A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
MX2020011552A (es) Combinaciones de variantes de anticuerpos y usos de las mismas.
MX382848B (es) Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
CL2019001583A1 (es) Nuevo anticuerpo anti-receptor de transferrina humana capaz de penetrar la barrera hematoencefálica.
CO2019012998A2 (es) Proteínas de unión a antígenos trem2 y usos de estas
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX387180B (es) Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
UY40733A (es) Un constructo de anticuerpo que comprende al menos tres dominios
PE20170665A1 (es) Anticuerpos anti-tau humanizados
UY37456A (es) Inmunoglobulinas y sus usos
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
GT200600186A (es) Agentes de unión
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201691787A1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
MX389320B (es) Anticuerpos anti-tnfrsf25
BR112018067897A2 (pt) imunoglobulinas modificadas com ligação de fcrn alterada
MX387451B (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.